AbbVie and Iambic announce multi-year AI drug discovery collaboration
AbbVie and clinical-stage biotech Iambic said they entered a multi-year collaboration to accelerate drug discovery using Iambic’s AI-driven platform.
AbbVie (NYSE:ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, on Sept. 21, 2026 announced a multi-year collaboration to accelerate the discovery and development of potential new medicines. The companies said the collaboration is intended to speed up work on novel medicines through Iambic’s AI-driven discovery and development platform.